Litigation Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)
✉ Email this page to a colleague
Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-06-01 |
| Court | District Court, D. Delaware | Date Terminated | 2019-03-11 |
| Cause | 35:271 Patent Infringement | Assigned To | Joseph F. Bataillon |
| Jury Demand | None | Referred To | Sherry R. Fallon |
| Parties | TARO PHARMACEUTICAL INDUSTRIES LTD. | ||
| Patents | 8,778,365; 9,517,219 | ||
| Attorneys | Kevin X. McGann | ||
| Firms | Phillips, Goldman, McLaughlin & Hall, P.A. | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Almirall LLC v. Taro Pharmaceutical Industries Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial and ⤷ Try a Trial .
Details for Almirall LLC v. Taro Pharmaceutical Industries Ltd. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-10-23 | 113 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2 . (Blumenfeld, Jack…2017 11 March 2019 1:17-cv-00663 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2019-01-23 | 137 | would induce infringement of U.S. Patent No. 9,517,219 (“the ’219 patent”) under the doctrine of equivalents…asserted claims are invalid. The ’219 patent is a method patent. The matter is set for trial on February…since the language of the asserted patent claims, and not the patent holder’s commercial product, to define… that during the prosecution of the ’219 patent, the patent examiner defined a POSA as having a level… a POSA for the ’219 patent. Taro proposes: A POSA for the ’219 patent would have had at least | External link to document | |
| 2017-11-01 | 34 | 424/400 Patent Number: 8,778,365 First Named Bhushan Hardas…prosecution of any patent application before the USPTO or any corresponding foreign patent authority that…partes review) before the USPTO on any patent-in- suit or any patent issued from any application that (…prosecute any patent application before the USPTO or any corresponding foreign patent authority that…prosecution of any patent application before the USPTO or any corresponding foreign patent authority that | External link to document | |
| 2017-11-27 | 39 | infringement of United States Patent No. 9,517,219 ("the '219 patent"), which is entitled …;Allergan") brought this civil action for patent infringement under the Hatch-Waxman Act on June…for Use Thereof. (D.I. 1 at if 18) The '219 patent encompasses the approved use of Allergan's…prosecution of the application leading to the '219 patent, which allegedly limited the claimed polymeric…multi-component PVB and the claimed PVB in the '219 patent is the proper subject of fact and expert discovery | External link to document | |
| 2017-06-01 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,517,219 B2. (nmg) (Entered:…2017 11 March 2019 1:17-cv-00663 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| 2018-06-06 | 87 | Report and Recommendations | alleges infringement of U.S. Patent No. 9,517,219 ("the '219 patent") under the doctrine …x27;219 patent. However, Allergan alleges that Taro's product infringes the '219 patent through…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…the '219 patent claims a PVB "comprising [A/SA] copolymer." ('219 patent, col. 16:8-… 7 '219 patent over the prior art by explaining that the '219 patent employs an A/SA copolymer | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
